A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis [PDF]
New England Journal of Medicine, 2012 BACKGROUND Ruxolitinib, a selective inhibitor of Janus kinase (JAK) 1 and 2, has clinically significant activity in myelofibrosis. METHODS In this double-blind trial, we randomly assigned patients with intermediate-2 or high-risk myelofibrosis to twice-
DiPersio, John F, et al,
core +3 more sources
Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial [PDF]
Journal of Hematology & Oncology, 2017 BackgroundThe randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial evaluated the JAK1/JAK2 inhibitor ruxolitinib in patients with intermediate-2/high-risk myelofibrosis.
DiPersio, John F, et al,
core +3 more sources
International Journal of Laboratory Hematology, Volume 47, Issue 3, Page 373-375, June 2025.
Sara Sacchetti +4 more
wiley +1 more source
Pulmonary arterial hypertension exacerbated by ruxolitinib [PDF]
, 2015 Harrison, C +3 more
core +2 more sources
Which patients with myelofibrosis should receive ruxolitinib therapy? ELN-SIE evidence-based recommendations [PDF]
, 2016 Barbui, T +12 more
core +1 more source
Platelet-derived growth factor receptor [béta] (PDGFR[béta]) immunohistochemistry highlights activated bone marrow stroma and is potentially predictive for fibrosis progression in prefibrotic myeloproliferative neoplasia [PDF]
, 2017 Anagnostopoulos, Ioannis +5 more
core +1 more source
Safety and efficacy of combined ruxolitinib and decitabine in accelerated and blast-phase myeloproliferative neoplasms [PDF]
, 2018 Abboud, Camille N.
core +1 more source
The Burden of Myelofibrosis In Greece [PDF]
Value in Health, 2014 M. Hatzikou +8 more
openaire +3 more sources
Phase 1/2 study of pacritinib, a next generation JAK2/FLT3 inhibitor, in myelofibrosis or other myeloid malignancies [PDF]
, 2016 core +1 more source